Adverse Event Reporting and Standardized Medical Terminologies: Strengths and Limitations

Abstract

The International Conference on Harmonization (ICH) is a unique multinational effort involving globalization of the pharmaceutical industry. In response to a need perceived by both industry and regulatory authorities for a common medical terminology designed for regulatory purposes, the Medical Dictionary for Regulatory Activities (MedDRA®) was developed under ICH auspices.

As a dynamic terminology, MedDRA has undergone review and refinements by its associated Expert Working Group to facilitate analysis and presentation of data. The MedDRA Maintenance and Support Services Organization is responsible for maintaining and updating the terminology, utilizing user experience and feedback.

While not the first coding terminology designed for adverse reaction reporting, MedDRA reportedly offers advantages over previous terminologies. Further, a common terminology provides for greater ease of analysis and data transmission both within and between countries.

However, no medical terminology is without limitations, particularly with respect to coding issues and specific clinical entities. These limitations must be recognized and considered in the performance of pharmacovigilance and pharmacoepidemiology, if the terminology's utility as a safety tool is to be maximized.

Keywords

Adverse Reporting MedDRA®Pharmacovigilance Pharmacoepidemiology

Get full access to this article

View all access options for this article.

References

International Conference on Harmonization Web site: www.ifpma.org/ich1.html; www.ifpma.org/ich5m.html; www.ifpma.org/ichMedDRA.html.

MedDRA Maintenance and Support Services Organization Website: www.meddramsso.com..

Goldman

Lithium and neuroleptics in combination: The spectrum of neurotoxicity. Psychopharmacol Bull. 1996;32(3):299–309.

Venulet

Bankowski

Harmonising adverse drug reaction terminology: The role of the Council for International Organizations of Medical Sciences. Drug Saf. 1998;19(3):165–172.

Council for International Organizations of Medical Sciences Working Group I. International Reporting of Adverse Drug Reactions, Final Report of CIOMS Working Group I. Geneva, Switzerland: Council for International Organizations of Medical Sciences; 1990.

Jones

Definition of events associated with drugs: Regulatory perspectives. J Rheumatology. 1988;15(Suppl 17):14–19.

Venulet

Establishing requirements for the use of terms for reporting adverse drug reactions. Int J Clin Pharmacol Res. 1992;12(2):61–64.

US Food and Drug Administration, Center for Drug Evaluation and Research. Coding Symbols for Thesaurus of Adverse Reaction Terms. Fifth edition. Rockville, MD: US Food and Drug Administration; 1995.

World Health Organization Collaborating Centre for International Drug Monitoring. Adverse Reaction Terminology. Uppsala, Sweden: World Health Organization; 1992.

10.

World Health Organization. International Statistical Classification of Diseases and Health Related Problems. Tenth revision. Geneva, Switzerland: World Health Organization; 1992.

11.

Wood

The Medical Dictionary for Drug Regulatory Affairs (MEDDRA) project. Pharmacoepidemiol Drug Saf. 1994;3:7–13.

12.

Kubota

Inman

WHW

Terminology in prescription-event monitoring. Eur J Clin Pharmacol. 1994;46(6):497–500.

13.

Breant

Borst

Campi

Griesser

Momjian

A hospital-wide clinical findings dictionary based on an extension of the International Classification of Diseases (ICD). Proc AMIA Symp. 1999;706–710.

14.

Huntley

Veverka

Golden

The FDA's Medical Dictionary for Drug Regulatory Affairs alpha test. Drug Inf J. 1995;29:1133–1143.

15.

White

A preliminary assessment of the impact of MEDDRA on adverse event reports and product labeling. Drug Inf J. 1998;32:347–362.

16.

Brown

Clark

Evaluation of MEDDRA in representing medicinal product data sheet information. Pharmaceutical Med. 1996;10:111–118.

17.

Brown

Wood

The Medical Dictionary for Regulatory Activities (MedDRA). Drug Saf. 1999;20(2):109–117.

18.

Goldman

Lithium and neuroleptics in combination: Is there enhancement of neurotoxicity leading to permanent sequelae?

J Clin Pharmacol. 1996;36(10):951–962.

19.

Caroff

Mann

Neuroleptic malignant syndrome. Med Clin North Am. 1993;77(1):185–202.

20.

Addonizio

Susman

Roth

Symptoms of neuroleptic malignant syndrome in 82 consecutive inpatients. Am J Psychiatry. 1986;143(12):1587–1590.

21.

Gurrera

Chang

Romero

A comparison of diagnostic criteria for neuroleptic malignant syndrome. J Clin Psychiatry. 1992;53(2):56–62.

22.

Brown

Douglas

Tabulation and analysis of pharmacovigilance data using the Medical Dictionary for Regulatory Activities. Pharmacoepidemiol Drug Saf. 2000;9(6): 479–489.